We know gout is among the many comorbidities that increase the risk of cardiovascular disease (CVD). In 2018, the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial concluded that febuxostat was non-inferior to allopurinol. BUT, two of the secondary endpoints were very concerning. Febuxostat was inferior to allopurinol in terms of cardiovascular death and all-cause mortality. Many clinicians were left wondering whether febuxostat was cardiotoxic …. or conversely, perhaps allopurinol was cardioprotective. Will another cardiovascular outcome trial provide greater clarity to guide clinical practice?
Guest Authors: Sophia Dietrich, PharmD and Michael W. Nagy, PharmD, BCACP
Guest Panelist: Dawn Fuke, PharmD, BCPS
Music by Good Talk
SDOH Matters Too! Patient and Care Team Perspectives on Screening for SDOH
Treating Depression and Anxiety: Dosing, Pharmacogenetics, and Our Learners
Complex Patient Case 4: Diabetes, CKD, and Psoriasis
Can Losing Weight Using Semaglutide Prevent a Heart Attack, Ack, Ack, Ack, Ack?
Prescription for Savings: The Clinical and Economic Impact of Pharmacist-Led Hypertension Management in the U.S.
Heartburn Headache: Cumulative PPI Use and Dementia Risk
Does Size Matter? The Surprising Impact of Cuff Size on Blood Pressure Readings
Defining the Role of Semaglutide in Obese Patients with Heart Failure with Preserved Ejection Fraction
Do Statins “REPRIEVE” People Living with HIV from CV Events?
Top Ten Things Every Clinician Should Know About the RSV Vaccines
Complex Patient Case 3: Treatment Resistant Hypertension
Should We Be Good SPORTs About Supplements for Cholesterol?
Is Telehealth the Hidden (Hyper)Link to Controlling Blood Pressure?
Personalized Pharmacotherapy for Hypertension: Examining Intra-patient Variability
Over-the-Counter Hearing Aids – Where Do They Fit?
Road to Recovery: Pharmacist-Delivered Comprehensive Medication Management in an SUD Clinic
Gender Affirming Care - Finding the Resources You Need
Water Wars: Dueling Diuretics - Chlorthalidone vs. Hydrochlorothiazide for Cardiovascular Event Reduction
Beyond Statins: Approaches to Lipid Lowering in 2023
Fixed Dose or Treat-to-Target: Does LODESTAR Guide Us on Statin Management?
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive